SCHEMBL8982140

SCHEMBL8982140

COc1cc2c(cc1OC)CN(CCCCNS(=O)(=O)c1cccc(C)c1)CC2

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 3/20 0.59
TMEM97 Q5BJF2 2/20 0.59
HTR7 P34969 5/20 0.58
ABCB1 P08183 1/20 0.53
DRD2 P14416 1/20 0.52
DRD3 P35462 1/20 0.52
KDM4E B2RXH2 1/20 0.52
TSHR P16473 1/20 0.52
MAPK1 P28482 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
HTR1A P08908 1/20 0.50
HTR2A P28223 1/20 0.50
SLC6A4 P31645 1/20 0.50
HTR2B P41595 1/20 0.50
KCNH2 Q12809 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4230108 0.99 SIGMAR1 (0.58) SIGMAR1TMEM97HTR7ABCB1DRD2
SCHEMBL10035588 0.97 HTR7 (0.57) SIGMAR1TMEM97HTR7ABCB1DRD2
Hydrochloric Acid SCHEMBL2136320 0.96 HTR7 (0.56) SIGMAR1TMEM97HTR7ABCB1DRD2
SCHEMBL8982250 0.90 DRD4 (0.58) HTR7ABCB1DRD3
SCHEMBL8981452 0.90 HTR7 (0.58) SIGMAR1TMEM97HTR7ABCB1DRD2
SCHEMBL8983429 0.90 HTR7 (0.72) SIGMAR1TMEM97HTR7ABCB1DRD2
SCHEMBL5410336 0.89 HTR7 (0.57) SIGMAR1TMEM97HTR7ABCB1DRD2
Hydrochloric Acid SCHEMBL4216217 0.89 HTR7 (0.57) SIGMAR1TMEM97HTR7ABCB1DRD2
SCHEMBL8983653 0.89 L3MBTL1 (0.61) SIGMAR1TMEM97HTR7ABCB1DRD2
Hydrochloric Acid SCHEMBL4228196 0.89 DRD4 (0.57) HTR7ABCB1DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188115-B2 5-HT7 receptor antagonists LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-05-29 US disclosed
US-8188115-B2 5-HT7 receptor antagonists LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-05-29 US disclosed
US-20090163542-A1 5-ht7 receptor antagonists LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-06-25 US disclosed
US-20090163542-A1 5-ht7 receptor antagonists LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-06-25 US disclosed
US-7211585-B2 5-HT7 receptor antagonists LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-05-01 US disclosed
US-7211585-B2 5-HT7 receptor antagonists LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163542-A1 5-ht7 receptor antagonists HTR7, HTR1A, HTR5A SIGMAR1 140/4885TMEM97 100/4885HTR7 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.